Esperion Therapeutics (ESPR) Appoints Robert E. Hoffman to its Board

Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025.

“We are pleased to welcome Robert to the Esperion Board, confident that his decades of leadership within the biopharmaceutical sector will be of great benefit as we engage in our commercialization efforts and expand our pipeline of next generation ACLY inhibitors,” said Sheldon Koenig, President and CEO of Esperion. “Robert is a well-regarded and skilled leader who brings a wealth of insights from his tenure in the sector. I am confident his deep domain expertise in the commercialization of medicines will be a valued resource as we continue to mature as a commercial organization.”

Mr. Koenig continued, “I extend my deep gratitude to Nicole and Dr. Gotto for their innumerable contributions and years of dedication to Esperion. We thank them for their service and wish them both the very best in their future endeavors.”

“I am delighted to have the opportunity to work closely with the Esperion team at this important time of its growth as a commercial organization,” said Mr. Hoffman. “I look forward to partnering with management and the board to support Esperion in their mission to bring new medicines to market to address the unmet cardiometabolic needs of patients and healthcare professionals.”

Mr. Hoffman served as President, CEO, interim Chief Financial Officer and Chairperson of the board of directors of Kintara Therapeutics, Inc. from 2021 to 2024. Mr. Hoffman previously served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc. from 2017 to 2020, and as Chief Financial Officer of AnaptysBio, Inc. from 2015 to 2016. From 2012 to 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. (“Arena”) until its sale to Pfizer in 2022 and held several roles of increasing responsibility at Arena from 1997 to 2011.

Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. He formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board, from 2010 to 2020.

Mr. Hoffman currently serves on the board of directors of TuHURA Biosciences and Fibrobiologics, Inc. and has served as a member of the board of directors of several public and private life sciences companies, including ASLAN Pharmaceuticals Limited, Saniona AB, Kura Oncology, Inc., CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc., and Aravive, Inc.

Mr. Hoffman holds a B.B.A. from St. Bonaventure University.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• United Airlines expands Denver pilot training center, phase two planned
• Musalem: strong growth and investment influencing bond market - CNBC